Seroatlas · Human Serome Atlas

LYZL1

Lysozyme-like protein 1

Also known as: LYC2, LYZL1_HUMAN, MGC33408

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q6UWQ5
Gene: LYZL1
Ensembl: ENSG00000120563
Chromosome: 10
Canonical length: 148 aa
Protein class: Enzymes, Metabolic proteins, Predicted intracellular proteins, Predicted secreted proteins
Secretome location: Secreted in male reproductive system

OverviewNCBI Gene

Predicted to enable lysozyme activity. Predicted to be located in extracellular region. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

148 residues, UniProt reviewed canonical sequence.

>Q6UWQ5|LYZL1
     1  MKAAGILTLI GCLVTGAESK IYTRCKLAKI FSRAGLDNYW GFSLGNWICM AYYESGYNTT
    61  AQTVLDDGSI DYGIFQINSF AWCRRGKLKE NNHCHVACSA LITDDLTDAI ICARKIVKET
   121  QGMNYWQGWK KHCEGRDLSE WKKGCEVS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against LYZL1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Secreted
Secreted: Yes
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.33
Highest tissue expression: 49 nTPM

Expression across tissuesHPA

Tissue

testis: 49 nTPM
liver: 0.1 nTPM
adipose tissue: 0 nTPM
adrenal gland: 0 nTPM
amygdala: 0 nTPM
appendix: 0 nTPM

Single-cell type

early spermatids: 586 nCPM
late primary spermatocytes: 427 nCPM
late spermatids: 264 nCPM
sertoli cells: 3.1 nCPM
retinal horizontal cells: 2 nCPM
leydig cells: 1.8 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

amygdala: 0 nTPM
basal ganglia: 0 nTPM
cerebellum: 0 nTPM
cerebral cortex: 0 nTPM
choroid plexus: 0 nTPM
hippocampal formation: 0 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.73
gnomAD pLI: 0
gnomAD missense Z: -0.02

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Molecular functions

lysozyme activity

Cellular components

extracellular region

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads LYZL1 as an antibody target. Whether an autoantibody or antibody against LYZL1 could matter depends on whether native LYZL1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

LYZL1 is annotated as secreted, so native LYZL1 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label LYZL1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...